ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
Avatar

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with MF

By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
52 views
December 17, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
MDS and MPN
06:20

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

115 views
07:13

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

156 views
10:26

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Studies:…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

311 views
06:04

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

ASH 2021 Conference Coverage on VuMedi

K. Kim

152 views
05:14

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

ASH 2021 Conference Coverage on VuMedi

E. Oliva

118 views
11:04

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

ASH 2021 Conference Coverage on VuMedi

J. Bewersdorf

123 views
06:52

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

97 views
11:17

ASH 2021 Updates on the Management of Polycythemia Vera

ASH 2021 Conference Coverage on VuMedi

A. Kuykendall

39 views
04:45

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

ASH 2021 Conference Coverage on VuMedi

A. Jain

98 views
08:59

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

ASH 2021 Conference Coverage on VuMedi

M. Shah

12 views
08:12

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

13 views
08:30

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

70 views
05:32

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

67 views
08:15

ASH 2021 Highlights in MPN

ASH 2021 Conference Coverage on VuMedi

P. Bose

249 views
15:25

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

88 views
10:43

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

ASH 2021 Conference Coverage on VuMedi

P. Bose

98 views
05:06

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

ASH 2021 Conference Coverage on VuMedi

F. Passamonti

141 views
13:17

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

ASH 2021 Conference Coverage on VuMedi

J. Garcia

75 views
12:03

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

ASH 2021 Conference Coverage on VuMedi

A. Brunner

72 views
06:27

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

ASH 2021 Conference Coverage on VuMedi

H. Gill

477 views
07:56

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

52 views
10:27

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

Richard T. Silver

329 views
10:44

A Real-World Evaluation of the Association Between Elevated Blood Co…

Aaron Gerds

1.1K views
15:40

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

ASH 2021 Conference Coverage on VuMedi

A. Tefferi

437 views
05:15

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

617 views